FDA Scrambles for New CBER Director After Prasad's Turbulent Tenure

With ophthalmologist Dr. Houman Hemmati emerging as frontrunner to lead the Center for Biologics Evaluation and Research, the FDA faces a credibility test. Prasad's departure leaves unfinished business: vaccine policy rewrites, accelerated approval reforms, and a demoralized biologics review staff.